Bull case
Spectral AI is attractive because its DeepView System addresses a large, under-penetrated burn and wound market with an estimated ~$3.7B TAM, targeting ~125 Burn Centers and ~5,000 Trauma and ED units in the US, while serving a need that includes ~490k burn patients annually in the US and ~87k in the UK. Its thesis is strengthened by the March 2026 BARDA funding of ~$31.7M, plus an additional $9.7M in committed development costs, which reduces financing risk and supports commercialization, while potential deployment of ~30 systems and subsidy for another ~140 systems could accelerate adoption. With FDA clearance now secured, a commercial launch expected in 2H26, and a functioning handheld prototype delivered ahead of expectation in early May 2026, the company has multiple catalysts that could support high-margin, recurring revenue growth as DeepView expands into broader indications.